Report Publication Announcement • Apr 18, 2016
Report Publication Announcement
Open in ViewerOpens in native device viewer
Buy recommendation with a target price of 18.8 euros per share*
Toulouse, FRANCE, Ann Arbor, UNITED STATES, April 18, 2016 – Cerenis Therapeutics (FR0012616852- CEREN), an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies ("good cholesterol") for treating cardiovascular and metabolic diseases, today announces the publication of an initiation of coverage report by PORTZAMPARC, with a target price of 18.8 euros per share*.
* This information does not constitute an offer to sell or subscribe or a solicitation to purchase or subscribe for securities in France, Europe, the United States or any other jurisdiction. The delivery of a service for financial analyses production and diffusion has been concluded between Cerenis Therapeutics and Portzamparc Société de bourse.
Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies for the treatment of cardiovascular and metabolic diseases. HDL is the primary mediator of the reverse lipid transport, or RLT, the only natural pathway by which excess cholesterol is removed from arteries and is transported to the liver for elimination from the body.
Cerenis is developing a portfolio of HDL therapies, including HDL mimetics for the rapid regression of atherosclerotic plaque in highrisk patients such as post-ACS patients and patients with HDL deficiency, and drugs which increase HDL for patients with low number of HDL particles to treat atherosclerosis and associated metabolic diseases.
Cerenis is well positioned to become one of the leaders in the HDL therapeutic market, with a broad portfolio of programs being developed.
Since its inception in 2005, the company has been funded by top tier investors: Sofinnova Partners, HealthCap, Alta Partners, EDF Ventures, Daiwa Corporate Investment, TVM Capital, Orbimed, IRDI/IXO Private Equity and Bpifrance (Fund for Strategic Investment) and last March successfully completed an IPO on Euronext raising €53.4m.
CER-001 is an engineered complex of recombinant human apoA-I, the major structural protein of HDL, and phospholipids. It has been designed to mimic the structure and function of natural, nascent HDL, also known as pre-beta HDL. Its mechanism of action is to increase apoA-I and the number of HDL particles transiently, to stimulate the removal of excess cholesterol and other lipids from tissues including the arterial wall and to transport them to the liver for elimination through a process called Reverse Lipid Transport. Previous Phase II studies have provided important data demonstrating the efficacy of CER-001 in regressing atherosclerosis in several distinct vascular beds in patients representing the entire spectrum of cholesterol homeostasis. The totality of the data to date indicates that CER-001 performs all of the functions of natural pre-beta HDL particles and has the potential to be the best-in-class HDL mimetic in the market.
CER-209 is the first drug candidate in the category of oral P2Y13 receptor agonists. The P2Y13 receptor is a member of the P2Y receptor family, a well-known receptor family including the P2Y12 receptor which is the target of successful drugs such as the antithrombotic agent Clopidogrel (Plavix®). In preclinical studies CER-209 promotes HDL recognition by the liver and increase the activity of Reverse Lipid Transport (RLT), and thus has an impact on atherosclerosis regression. Because of the favorable metabolic effects observed in the liver, CER-209 may also offer a new mechanism for the treatment of non-alcoholic steatohepatitis (NASH).
Jean-Louis Dasseux CEO [email protected] Tel: +33 (0)5 62 24 09 49
Investors relations Emmanuel Huynh / Louis-Victor Delouvrier [email protected] Tel: +33 (0)1 44 71 98 53
NewCap Media relations Nicolas Merigeau [email protected] Tel: +33 (0)1 44 71 94 98
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.